Previous clinical trials of agents developed to treat Ebola have shown monoclonal neutralizing antibodies can reduce viremia, attenuate virulence, substantially improve clinical symptoms and reduce the mortality of those infected.
========================================================
部分内容来自网络,如有版权问题请与我们联系
未经许可,严禁转发。QQ交流群:688169419
========================================================